Core A: Biospecimen Processing

Director: Peter Westervelt, MD, PhD

The Biospecimen Processing Core (Core A) will be responsible for the identification and enrollment of every patient referred to the Siteman Cancer Center with newly diagnosed and relapsed hematologic malignancy (excluding multiple myeloma). The pathologic material from these patients will be banked using the existing Siteman Cancer Center (SCC) Tissue Processing Core (TPC), and clinical data will be tracked prospectively in a clinical database. The Biospecimen Processing Core has three specific aims:

Specific aim 1: We will prospectively identify and bank specimens from all patients with newly diagnosed or relapsed myelodysplastic syndrome, myeloproliferative disorder, and acute or chronic leukemia referred to Washington University Siteman Cancer Center.

Specific aim 2: We will maintain a comprehensive clinical database that will capture epidemiological data, disease-related characteristics, prognostic factors, treatment, and outcomes from all newly diagnosed and relapsed hematologic malignancy patients referred to the Siteman Cancer Center.

Specific aim 3: We will develop a comprehensive and transparent plan to catalog the biospecimens collected in Core A and facilitate their distribution to the broader scientific community of hematologic malignancy investigators.